JP2006517944A5 - - Google Patents

Download PDF

Info

Publication number
JP2006517944A5
JP2006517944A5 JP2006501881A JP2006501881A JP2006517944A5 JP 2006517944 A5 JP2006517944 A5 JP 2006517944A5 JP 2006501881 A JP2006501881 A JP 2006501881A JP 2006501881 A JP2006501881 A JP 2006501881A JP 2006517944 A5 JP2006517944 A5 JP 2006517944A5
Authority
JP
Japan
Prior art keywords
palonosetron
composition
use according
comprises orally
orally liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006501881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517944A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/001558 external-priority patent/WO2004073714A1/en
Publication of JP2006517944A publication Critical patent/JP2006517944A/ja
Publication of JP2006517944A5 publication Critical patent/JP2006517944A5/ja
Pending legal-status Critical Current

Links

JP2006501881A 2003-02-18 2004-02-18 手術後の悪心嘔吐を治療するパロノセトロンの使用 Pending JP2006517944A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44834203P 2003-02-18 2003-02-18
PCT/EP2004/001558 WO2004073714A1 (en) 2003-02-18 2004-02-18 Use of palonosetron treating post-operative nausea and vomiting

Publications (2)

Publication Number Publication Date
JP2006517944A JP2006517944A (ja) 2006-08-03
JP2006517944A5 true JP2006517944A5 (https=) 2007-04-05

Family

ID=32908576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006501881A Pending JP2006517944A (ja) 2003-02-18 2004-02-18 手術後の悪心嘔吐を治療するパロノセトロンの使用

Country Status (31)

Country Link
US (1) US20060074101A1 (https=)
EP (2) EP1596862B1 (https=)
JP (1) JP2006517944A (https=)
KR (1) KR101113087B1 (https=)
CN (1) CN1750822A (https=)
AT (1) ATE490774T1 (https=)
AU (1) AU2004212704B2 (https=)
BR (1) BRPI0407549A (https=)
CA (1) CA2515946C (https=)
CU (1) CU23587B7 (https=)
CY (1) CY1111312T1 (https=)
DE (1) DE602004030424D1 (https=)
DK (1) DK1596862T3 (https=)
EA (1) EA013836B1 (https=)
EC (1) ECSP055970A (https=)
ES (1) ES2357769T3 (https=)
GE (1) GEP20104908B (https=)
HR (1) HRP20050709A2 (https=)
IS (1) IS7983A (https=)
MX (1) MXPA05008757A (https=)
MY (1) MY143789A (https=)
NO (1) NO20054296L (https=)
NZ (1) NZ541862A (https=)
PL (1) PL378122A1 (https=)
PT (1) PT1596862E (https=)
SI (1) SI1596862T1 (https=)
TW (1) TWI355936B (https=)
UA (1) UA96254C2 (https=)
UY (1) UY28193A1 (https=)
WO (1) WO2004073714A1 (https=)
ZA (1) ZA200506580B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
RU2428176C2 (ru) * 2006-01-27 2011-09-10 Юранд, Инк. Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
CN101573106B (zh) * 2006-10-24 2013-07-24 赫尔辛医疗股份公司 具有改进的稳定性和生物利用度的含帕洛司琼盐酸盐的软胶囊剂
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US20090155363A1 (en) * 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
JP5547065B2 (ja) 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
WO2010077669A2 (en) * 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
CN102458400B (zh) 2009-05-20 2014-10-08 国立健康与医学研究所 用于治疗病灶性前庭功能障碍的血清素5-ht3受体拮抗剂
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20120253046A1 (en) 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
PT2722045T (pt) 2009-11-18 2016-10-18 Helsinn Healthcare Sa Composições para o tratamento de náuseas e vómitos mediadas centralmente
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
WO2014004126A1 (en) 2012-06-26 2014-01-03 Fleming C Andrew Treating postoperative nausea and vomiting
US9877959B2 (en) 2013-12-23 2018-01-30 Samyang Biopharmaceuticals Corporation Pharmaceutical composition containing palonosetron
RS65379B1 (sr) 2016-04-14 2024-04-30 Sensorion (+)-azasetron za upotrebu u lečenju poremećaja uha
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
WO2019138162A1 (en) * 2018-01-12 2019-07-18 Orion Corporation Palonosetron for the treatment or prevention of nausea and vomiting
CN108703960A (zh) * 2018-07-25 2018-10-26 无锡鑫连鑫生物医药科技有限公司 一种帕洛诺司琼缓释微球及其制备方法和使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3687080T2 (de) 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US4707484A (en) 1986-11-25 1987-11-17 Hoffmann-La Roche Inc. Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
PL166272B1 (pl) * 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5491148A (en) 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5492914A (en) 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
CA2321191A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht3 receptors
DK1124535T3 (da) * 1998-10-27 2003-01-06 Alcon Lab Inc Konserverende system til topisk indgivelige farmaceutiske præparater indeholdende en fedtsyre/aminosyresæbe
US6196963B1 (en) * 1999-03-02 2001-03-06 Medtronic Ave, Inc. Brachytherapy device assembly and method of use
AU2003237657A1 (en) * 2002-05-24 2003-12-12 Epidauros Biotechnologie Ag Means and methods for improved treatment using "setrones"
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) * 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron

Similar Documents

Publication Publication Date Title
JP2006517944A5 (https=)
JP2006213929A5 (https=)
JP2006503588A5 (https=)
JP2005526147A5 (https=)
CL2007001992A1 (es) Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
CL2007001132A1 (es) Compuestos derivados de purina sustituida con otros sistemas heterociclicos; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP2009538898A5 (https=)
CL2006002831A1 (es) Compuestos derivados de sulfonamida: proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por el receptor de glucocorticoides.
JP2007520565A5 (https=)
JP2005515295A5 (https=)
JP2009520682A5 (https=)
JP2008534513A5 (https=)
JP2008515980A5 (https=)
JP2005524670A5 (https=)
DK1837019T3 (da) Orale dispergerbare farmaceutiske sammensætninger
JP2004529205A5 (https=)
JP2006525972A5 (https=)
JP2008523232A5 (https=)
JP2008517002A5 (https=)
JP2008533990A5 (https=)
JP2009509934A5 (https=)